ES2162051T3 - Preparacion dermatologica para tratar queratosis actinicas. - Google Patents

Preparacion dermatologica para tratar queratosis actinicas.

Info

Publication number
ES2162051T3
ES2162051T3 ES96912861T ES96912861T ES2162051T3 ES 2162051 T3 ES2162051 T3 ES 2162051T3 ES 96912861 T ES96912861 T ES 96912861T ES 96912861 T ES96912861 T ES 96912861T ES 2162051 T3 ES2162051 T3 ES 2162051T3
Authority
ES
Spain
Prior art keywords
actinic keratosis
dermatological preparation
treat actinic
composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96912861T
Other languages
English (en)
Inventor
Bruce E Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2162051T3 publication Critical patent/ES2162051T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

UNA COMPOSICION PARA EL TRATAMIENTO DE QUERATOSIS ACTINICA INCLUYE 5 LA COMPOSICION PUEDE INCLUIR ADICIONALMENTE INGREDIENTES AUXILIARES. SE DESCUBRE ASIMISMO UN METODO TERAPEUTICO QUE IMPLICA LA COMPOSICION Y UN KIT PARA LLEVAR A CABO EL TRATAMIENTO.
ES96912861T 1995-04-12 1996-04-10 Preparacion dermatologica para tratar queratosis actinicas. Expired - Lifetime ES2162051T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/421,674 US5627187A (en) 1995-04-12 1995-04-12 5-FU for treating actinic kerotoses

Publications (1)

Publication Number Publication Date
ES2162051T3 true ES2162051T3 (es) 2001-12-16

Family

ID=23671557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96912861T Expired - Lifetime ES2162051T3 (es) 1995-04-12 1996-04-10 Preparacion dermatologica para tratar queratosis actinicas.

Country Status (12)

Country Link
US (2) US5627187A (es)
EP (1) EP0822816B1 (es)
AT (1) ATE203907T1 (es)
AU (1) AU707853B2 (es)
CA (1) CA2215840A1 (es)
DE (1) DE69614375T2 (es)
DK (1) DK0822816T3 (es)
ES (1) ES2162051T3 (es)
GR (1) GR3037031T3 (es)
IL (1) IL117882A0 (es)
PT (1) PT822816E (es)
WO (1) WO1996032112A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
IL140005A0 (en) * 1998-06-26 2002-02-10 Aventis Pharm Prod Inc Method of treatment for dermatological disorders and compositions therefor
DE60131177T2 (de) * 2000-09-06 2008-08-07 AP Pharma, Inc., Redwood Abbaubare polyacetal-polymere
US6670335B2 (en) 2001-03-05 2003-12-30 A. P. Pharma, Inc. Fluorouracil-containing formulation
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
EP1509256B1 (en) * 2002-05-24 2009-07-22 Angiotech International Ag Compositions and methods for coating medical implants
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
WO2005007129A2 (en) * 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2143421A1 (en) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) * 1957-08-06 S-eluorourace
US2000213A (en) * 1932-07-18 1935-05-07 Standard Brands Inc Process for the manufacture of hydroxy carboxylic acids
US2265945A (en) * 1938-04-09 1941-12-09 Du Pont Organic acid synthesis
US2382889A (en) * 1941-07-22 1945-08-14 Lock Ritchie Hart Manufacture of lactic acid and salts thereof
US2970084A (en) * 1958-01-21 1961-01-31 Miles Lab Production of citric acid by fermentation
US3114770A (en) * 1959-01-20 1963-12-17 Orandi & Massera Sa Ind & Com Recovery of tartaric acid, as the calcium salt, from wine dregs
US2972566A (en) * 1959-12-07 1961-02-21 Kyowa Hakko Kogyo Kk Process for the production of l-malic acid
US3063910A (en) * 1960-02-03 1962-11-13 Kyowa Hakko Kogyo Kk Method of producing l-malic acid by fermentation
US3274074A (en) * 1963-10-24 1966-09-20 Kerr Mc Gee Oil Ind Inc Preparation of salicyclic acid by microbiological oxidation of naphthalene in the presence of a boron compound
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4363815A (en) * 1975-07-23 1982-12-14 Yu Ruey J Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5326790A (en) * 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
KR0133555B1 (ko) * 1989-01-05 1998-04-23 오오쓰까 아끼히꼬 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
DE19505328C1 (de) * 1995-02-17 1996-06-20 Boehringer Mannheim Gmbh Verwendung von Fluoruracil zur Behandlung von Nagelpilz
DE19549330A1 (de) * 1995-02-17 1996-08-22 Boehringer Mannheim Gmbh Mittel zur Behandlung von Nagelpilz

Also Published As

Publication number Publication date
MX9707850A (es) 1998-08-30
US5627187A (en) 1997-05-06
DE69614375T2 (de) 2002-05-23
DK0822816T3 (da) 2001-11-12
US5817666A (en) 1998-10-06
GR3037031T3 (en) 2002-01-31
CA2215840A1 (en) 1996-10-17
AU707853B2 (en) 1999-07-22
DE69614375D1 (de) 2001-09-13
PT822816E (pt) 2002-01-30
ATE203907T1 (de) 2001-08-15
AU5553596A (en) 1996-10-30
EP0822816A1 (en) 1998-02-11
WO1996032112A1 (en) 1996-10-17
EP0822816B1 (en) 2001-08-08
EP0822816A4 (en) 1998-12-30
IL117882A0 (en) 1996-08-04

Similar Documents

Publication Publication Date Title
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
PT880350E (pt) Tratamento de esclerose multipla
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE3850109T2 (de) 13-trans-retinsäureester.
NO981392L (no) Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinµrterapi som antiinflammatorisk middel
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
ZA903339B (en) Method of topically treating acne vulgaris
CA2002859A1 (en) Method of treating epithelial disorders
MY104412A (en) Acne treatment.
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
ES2111355T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para el tratamiento de dermatosis.
NO983864L (no) Morfin- og diamorfinsalter av anioniske, ikke-narkotiske analgetika av den substituerte karboksyltypen
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
GB2210789A (en) Topical application for skin care
PT100415A (pt) Novas morfolinas de accao farmaceutica, e processo para a sua preparacao
CA2270558A1 (en) Treatment of autoimmune diseases by photochemotherapy
BG101126A (en) The use of muramylpeptide compounds
FI925944A0 (fi) Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
ES2006121A6 (es) Procedimiento para la preparacion de una composicion farmaceutica destinada al tratamiento de enfermedades cutaneas.
ES2122236T3 (es) Sal de lisina de la 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida.
GB8928609D0 (en) Pharmaceutical composition
GEP19981196B (en) Ointment for Treatment of Keratosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 822816

Country of ref document: ES